Tanespimycin (17-AAG)

Name: Tanespimycin (17-AAG)
Brand: Selleck Chemicals
SKU: S1141
Rating: 5 (81 reviews)

For research use only.

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

81 publications

Tanespimycin (17-AAG) Chemical Structure

CAS No. 75747-14-7

Tanespimycin (17-AAG, CP127374, NSC-330507, KOS 953) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Tanespimycin (17-AAG) induces apoptosis, necrosis, autophagy and mitophagy. Phase 3.

Selleck's Tanespimycin (17-AAG) has been cited by 81 publications

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Cell Rep, 2020, 33(7):108397

PubMed: 33207204 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(4)

PubMed: 32272809 ( click the link to review the publication )

Mol Cell Biol, 2020,

PubMed: 32868290 ( click the link to review the publication )

Mol Cell Biol, 2020, MCB.00473-20

PubMed: 33139492 ( click the link to review the publication )

Phytomedicine, 2020,

PubMed: 32896707 ( click the link to review the publication )

Drug Des Devel Ther, 2020, 14:4605-4612

PubMed: 33149557 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Cell, 2019, 75(4):823-834

PubMed: 31302001 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5043

PubMed: 31695040 ( click the link to review the publication )

Cell Syst, 2019, 8(2):97-108

PubMed: 30797775 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):737

PubMed: 31570706 ( click the link to review the publication )

Cells, 2019, 8(8)

PubMed: 31370342 ( click the link to review the publication )

Front Cell Dev Biol, 2019, 7:204

PubMed: 31608279 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29283

PubMed: 31595984 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(2):220-233

PubMed: 31516744 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5637

PubMed: 30948782 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )
Exp Eye Res, 2019, 189:107821

PubMed: 31589841 ( click the link to review the publication )

Mol Cell Biol, 2019, 39(4)e00375-18

PubMed: 30455251 ( click the link to review the publication )

J Natl Cancer Inst, 2018, 110(4):390-399

PubMed: 29202196 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mol Oncol, 2018,

PubMed: 29797762 ( click the link to review the publication )

J Cell Biochem, 2018, 10.1002/jcb.27397

PubMed: 30378153 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

Eur J Med Chem, 2018, 158:548-558

PubMed: 30243156 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

EMBO J, 2017, 36(5):646-663

PubMed: 28093501 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28619760 ( click the link to review the publication )

Hum Mol Genet, 2017, 26(22):4465-4480

PubMed: 28973376 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4546

PubMed: 28674407 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 329:282-292

PubMed: 28624441 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Medchemcomm, 2017, 8(1):88-95

PubMed: 28670440 ( click the link to review the publication )
Oncotarget, 2017, 8(62):105372-105382

PubMed: 29285257 ( click the link to review the publication )

Nat Commun, 2016, 7:13122

PubMed: 27959342 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2089

PubMed: 26866270 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem J, 2016, 473(12):1733-44

PubMed: 27059856 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Stem Cells, 2015, 33(9):2738-47

PubMed: 26077647 ( click the link to review the publication )

Cancer Biol Ther, 2015,

PubMed: 25692408 ( click the link to review the publication )

Oncotarget, 2015, 6(17):14796-813

PubMed: 26142707 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )
Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

Sci Transl Med, 2012, 4(120):120ra17

PubMed: 22277784 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rMZ2lEPTB;MD6wNFA{ODNizszN	NHfKNZdUSU6JRWK=
IST-MEL1	NYjyZYxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LLWmlEPTB;MD6wNFA1ODdizszN	NXXq[mhpW0GQR1XS
NCI-SNU-1	NIrKWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMECyNFch\|ryP	MVvTRW5ITVJ?
FADU	NIPOS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMECyNFkh\|ryP	MVfTRW5ITVJ?
C32	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrCTWM2OD1yLkCwN\|A1KM7:TR?=	Ml3vV2FPT0WU
D-566MG	NWq1O\|dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXiTWM2OD1yLkCwN\|kh\|ryP	MVXTRW5ITVJ?
LXF-289	NYPobXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7jR49KSzVyPUCuNFA1OTlizszN	NWjROXZnW0GQR1XS
HGC-27	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwMEC1NUDPxE1?	MVTTRW5ITVJ?
RPMI-7951	NHnUNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzHfIdKSzVyPUCuNFA4OTdizszN	NG\DTJpUSU6JRWK=
HSC-3	NVLndIRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXHIUZFoUUN3ME2wMlAxQTJ7IN88US=>	MVHTRW5ITVJ?
MIA-PaCa-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;MeGlEPTB;MD6wNVAxQSEQvF2=	Ml7BV2FPT0WU
KS-1	NULI[mR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rCVmlEPTB;MD6wNVM2PSEQvF2=	Mn;0V2FPT0WU
CAL-51	M1PxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTSR\|c{UUN3ME2wMlAyPDB3IN88US=>	M2XiRXNCVkeHUh?=
MDA-MB-361	NULMZXVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXHdIJKUUN3ME2wMlAyPDl3IN88US=>	M1Pt[3NCVkeHUh?=
TI-73	Mn3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMEG3PVYh\|ryP	MVnTRW5ITVJ?
AGS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMEG5N\|gh\|ryP	M17UUnNCVkeHUh?=
NCI-H460	Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fnTmlEPTB;MD6wNVk4PCEQvF2=	MYnTRW5ITVJ?
A204	M{jCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13UeGlEPTB;MD6wNlI1QSEQvF2=	NW[1RmRLW0GQR1XS
CHL-1	NI\IbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnrTWM2OD1yLkCyNlUyKM7:TR?=	Mle4V2FPT0WU
DU-4475	MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGKzWXJKSzVyPUCuNFIzPjFizszN	NFnSdY5USU6JRWK=
CGTH-W-1	NH3jZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTBwMEKzOFkh\|ryP	MXzTRW5ITVJ?
HCC2218	NVHvXWZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LPZWlEPTB;MD6wNlQ6PCEQvF2=	MlvaV2FPT0WU
A2780	MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEK1N\|Eh\|ryP	NV70TmwzW0GQR1XS
NCI-H720	MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX6yU2V6UUN3ME2wMlAzPTR4IN88US=>	M13lb3NCVkeHUh?=
NCI-N87	NH36dopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGW4VJJKSzVyPUCuNFI2QTNizszN	MkmwV2FPT0WU
CHP-212	M1LFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMEK2Nlgh\|ryP	MmPaV2FPT0WU
NCI-H23	MkLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH60SFdKSzVyPUCuNFI3PjVizszN	NWfydXV2W0GQR1XS
D-263MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1y5VWlEPTB;MD6wNlc5PiEQvF2=	M2DsWHNCVkeHUh?=
ME-180	NIHHfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7uTGdKSzVyPUCuNFI5QTFizszN	NETDS3FUSU6JRWK=
SW982	M16zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV2xfYtQUUN3ME2wMlAzQTl7IN88US=>	MVTTRW5ITVJ?
OE19	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHPPVlKSzVyPUCuNFMxPzdizszN	MlPtV2FPT0WU
SK-LU-1	NIPYZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljsTWM2OD1yLkCzNFgzKM7:TR?=	MlfVV2FPT0WU
H4	MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDQcHVKSzVyPUCuNFMxQSEQvF2=	MmrhV2FPT0WU
HT-144	M2L6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEOwPVMh\|ryP	NH6wTYRUSU6JRWK=
SK-UT-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\YcHlYUUN3ME2wMlA{OTd6IN88US=>	NYqwcZFpW0GQR1XS
D-336MG	NUjh[mxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHpTWM2OD1yLkCzN\|A6KM7:TR?=	NEHJO5ZUSU6JRWK=
MDA-MB-175-VII	NFXPc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrVPZRKSzVyPUCuNFM{PTRizszN	MU\TRW5ITVJ?
GAMG	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\6RXE4UUN3ME2wMlA{PDN3IN88US=>	NFvqTYVUSU6JRWK=
CP50-MEL-B	M{Dlcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{O1cWlEPTB;MD6wN\|Q2KM7:TR?=	NVXBcpNMW0GQR1XS
OVCAR-5	M4P5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFT5bY9KSzVyPUCuNFM1QCEQvF2=	M{i1WnNCVkeHUh?=
SK-MES-1	M3Lp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMEO2NFYh\|ryP	M{O4O3NCVkeHUh?=
VM-CUB-1	M3jNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX61WVM5UUN3ME2wMlA{PjV5IN88US=>	MXHTRW5ITVJ?
WM-115	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnYWWZmUUN3ME2wMlA{PzZ{IN88US=>	NHW4TZJUSU6JRWK=
DSH1	NXSxc5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWj0b3lyUUN3ME2wMlA{QDB5IN88US=>	MlXsV2FPT0WU
Becker	NFLVeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwMEO4PFUh\|ryP	Mk\tV2FPT0WU
SW962	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnZUmxKSzVyPUCuNFM6PDVizszN	NXLMd5NxW0GQR1XS
TYK-nu	M{DHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMEO5PFUh\|ryP	NWTNdWVmW0GQR1XS
HO-1-N-1	MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILMSmZKSzVyPUCuNFQxOjFizszN	NHXXcHpUSU6JRWK=
T98G	NHj0eJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLqU49KSzVyPUCuNFQyODNizszN	M{LBWXNCVkeHUh?=
ACN	NF21NVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHuV49OUUN3ME2wMlA1OTZ{IN88US=>	NG[wcHpUSU6JRWK=
SW780	NFvwW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILTXGVKSzVyPUCuNFQzODNizszN	MmX3V2FPT0WU
Detroit562	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zIeWlEPTB;MD6wOFI{QSEQvF2=	MV3TRW5ITVJ?
BB49-HNC	Mn3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTBwMESyOFMh\|ryP	NG\x[INUSU6JRWK=
HN	NU\IXGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTBwMESyO\|Ih\|ryP	MWLTRW5ITVJ?
H9	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fEXmlEPTB;MD6wOFM4OSEQvF2=	Mo\YV2FPT0WU
VA-ES-BJ	MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfWTWM2OD1yLkC0OFQ4KM7:TR?=	NGLodlNUSU6JRWK=
MEL-JUSO	NEjXOG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfB[5dZUUN3ME2wMlA1PDd3IN88US=>	Mlz3V2FPT0WU
BT-474	NFvacVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LwVWlEPTB;MD6wOFUh\|ryP	MXrTRW5ITVJ?
CaR-1	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3flPWlEPTB;MD6wOFU1QSEQvF2=	M4PV[HNCVkeHUh?=
PSN1	NWPxOYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXETWM2OD1yLkC0OlA{KM7:TR?=	NVe5O2M3W0GQR1XS
KYSE-510	M4DadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILvPGtKSzVyPUCuNFQ3PDlizszN	NGmyW25USU6JRWK=
KP-4	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nFSWlEPTB;MD6wOFc2OyEQvF2=	NUXSWHhRW0GQR1XS
KYSE-410	MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TxNGlEPTB;MD6wOFc4OiEQvF2=	MoPTV2FPT0WU
G-402	M{fTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkGxTWM2OD1yLkC0O\|g6KM7:TR?=	NUnxblZNW0GQR1XS
DOK	M3vHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwMES5NFIh\|ryP	M4fWZnNCVkeHUh?=
COR-L88	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjIe5p[UUN3ME2wMlA1QTF{IN88US=>	MoPLV2FPT0WU
SKG-IIIa	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzRTWM2OD1yLkC0PVg3KM7:TR?=	MnH6V2FPT0WU
AN3-CA	NG[z[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTBwMEWg{txO	MnLBV2FPT0WU
SW48	M4fPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{C5WWlEPTB;MD6wOVA{QSEQvF2=	M2T4OXNCVkeHUh?=
YKG-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnvTWM2OD1yLkC1NFcyKM7:TR?=	NYLhb4l6W0GQR1XS
KYSE-150	MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPBTndKSzVyPUCuNFUzOzVizszN	MVXTRW5ITVJ?
HuO-3N1	NELUVm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[5[mlEPTB;MD6wOVI{PyEQvF2=	NIfy[XBUSU6JRWK=
LB1047-RCC	M1[0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTSfZpKSzVyPUCuNFUzQTZizszN	NUDpenFvW0GQR1XS
NCI-H2030	NYnJeYpjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXWSW1KSzVyPUCuNFU1OTRizszN	NHHKO5RUSU6JRWK=
YH-13	NHi0bZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPWeYV7UUN3ME2wMlA2PzJ{IN88US=>	MkjjV2FPT0WU
5637	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLXTYQ{UUN3ME2wMlA2PzRizszN	NULTRW9VW0GQR1XS
LOXIMVI	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEW4O\|Ih\|ryP	MnHBV2FPT0WU
GT3TKB	NFzGN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHGTWM2OD1yLkC1PVQzKM7:TR?=	Mn\2V2FPT0WU
TCCSUP	M4\0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLmSZpKSzVyPUCuNFU6PjRizszN	M{TjWXNCVkeHUh?=
EPLC-272H	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3G5RmlEPTB;MD6wOlIxPSEQvF2=	NXfrcm1DW0GQR1XS
LU-99A	MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDXTWM2OD1yLkC2NlM4KM7:TR?=	NUf4[Vl4W0GQR1XS
NCI-H1755	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjrTWpKSzVyPUCuNFY{PDFizszN	M3uzWXNCVkeHUh?=
KM12	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7OTWM2OD1yLkC2N\|Q5KM7:TR?=	Mmj3V2FPT0WU
SF295	M2TBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwME[0OVIh\|ryP	NGTnOVFUSU6JRWK=
MZ2-MEL	M2rSTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrXOHJKSzVyPUCuNFY2PTNizszN	MVnTRW5ITVJ?
HEC-1	Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[0TWM2OD1yLkC2OVg5KM7:TR?=	NGLkbpZUSU6JRWK=
SW684	NEf4UHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP1WlVHUUN3ME2wMlA3PTlzIN88US=>	NHW4NoJUSU6JRWK=
SF539	NIHTRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDI[YtqUUN3ME2wMlA3PjhzIN88US=>	NFnNUmNUSU6JRWK=
GMS-10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu4fWJKSzVyPUCuNFY3QTlizszN	M2HNRXNCVkeHUh?=
MV-4-11	M2XaV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnkOndWUUN3ME2wMlA3QDB\|IN88US=>	MYPTRW5ITVJ?
HT-29	MnTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDs[25uUUN3ME2wMlA3QTF7IN88US=>	MmnDV2FPT0WU
23132-87	NYnWT4NoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\B[JRnUUN3ME2wMlA3QTVizszN	MUnTRW5ITVJ?
SW620	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYqxUHR3UUN3ME2wMlA4ODJ4IN88US=>	NVzqUIRQW0GQR1XS
HCC1806	MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDqU3VFUUN3ME2wMlA4OTNzIN88US=>	NVy5W5NVW0GQR1XS
Hs-578-T	NWnifYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7MTWM2OD1yLkC3NlA5KM7:TR?=	M37MTXNCVkeHUh?=
A2058	NVTlfHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMEeyNlgh\|ryP	MWnTRW5ITVJ?
MEL-HO	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mne2TWM2OD1yLkC3NlU2KM7:TR?=	MmX0V2FPT0WU
HCC2998	NHjPR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrjT4tKSzVyPUCuNFc{PDdizszN	MUXTRW5ITVJ?
HuO9	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTlTWM2OD1yLkC3OVg6KM7:TR?=	MnP6V2FPT0WU
CAL-39	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmOzTWM2OD1yLkC3O\|Y3KM7:TR?=	MoXnV2FPT0WU
M14	M1\FbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTxcHZKSzVyPUCuNFc6OTNizszN	NVPv[YJUW0GQR1XS
BFTC-909	NYnOS2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfoemtKSzVyPUCuNFc6PjlizszN	MnW3V2FPT0WU
TE-11	MlX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTBwMEe5PVYh\|ryP	NGHTcGZUSU6JRWK=
TGBC1TKB	M1:yemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfFbmlrUUN3ME2wMlA5ODR\|IN88US=>	NHvhSXpUSU6JRWK=
L-363	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVfJR\|UxRTBwMEiyNFYh\|ryP	NFfNeXdUSU6JRWK=
A431	Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWq1b41jUUN3ME2wMlA5OjFizszN	NVfrZXlbW0GQR1XS
MKN45	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojRTWM2OD1yLkC4NlE6KM7:TR?=	MYHTRW5ITVJ?
HT-1080	NVP1TnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnf1TWM2OD1yLkC4OFM6KM7:TR?=	MXXTRW5ITVJ?
OVCAR-8	M3\tcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\JTWM2OD1yLkC4OlIzKM7:TR?=	NITlbo5USU6JRWK=
LCLC-97TM1	M4LSWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjaTWM2OD1yLkC4O\|I5KM7:TR?=	NYDRPJpyW0GQR1XS
M059J	NF3jZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDGTWM2OD1yLkC5NFI4KM7:TR?=	M3zxXnNCVkeHUh?=
SK-MEL-2	M1LLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnroTWM2OD1yLkC5NFYh\|ryP	NHrvZ4ZUSU6JRWK=
TE-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HlZWlEPTB;MD6wPVIxPCEQvF2=	MnHQV2FPT0WU
KYSE-180	M4DLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPJN29KSzVyPUCuNFkzPjJizszN	NV\4NIRVW0GQR1XS
D-247MG	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPiNFNJUUN3ME2wMlA6PDV3IN88US=>	MoXJV2FPT0WU
8-MG-BA	MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTrPYhCUUN3ME2wMlA6PDd{IN88US=>	M3;zdHNCVkeHUh?=
NCI-H1792	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIToOXlKSzVyPUCuNFk3OThizszN	NGPPN4pUSU6JRWK=
MCF7	NXTlWoNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jNT2lEPTB;MD6wPVY4PyEQvF2=	MmDaV2FPT0WU
NCI-H2122	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfJTWM2OD1yLkC5O\|Q2KM7:TR?=	M{DoPXNCVkeHUh?=
EFO-27	NHO2XJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{X5XmlEPTB;MD6wPVk6PyEQvF2=	NUfLcmNqW0GQR1XS
LB2241-RCC	M3PBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTlTWM2OD1yLkGwNFU1KM7:TR?=	NUnRb4ZrW0GQR1XS
SN12C	M325TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUC0dWVOUUN3ME2wMlExOTB5IN88US=>	M3[2ZXNCVkeHUh?=
A498	M1jrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPONZBTUUN3ME2wMlExOThizszN	MVLTRW5ITVJ?
PANC-03-27	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDQTWM2OD1yLkGwNlg3KM7:TR?=	MofwV2FPT0WU
NCI-H1581	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\FfWlEPTB;MD6xNFI6KM7:TR?=	NIHJRWZUSU6JRWK=
U-87-MG	NVu3PXEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4S3eGlEPTB;MD6xNFMxPyEQvF2=	NGnGVVhUSU6JRWK=
G-401	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nRNWlEPTB;MD6xNFM2OyEQvF2=	M{DPNXNCVkeHUh?=
SiHa	M1K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXu1WWtCUUN3ME2wMlExPDh4IN88US=>	M2L4fnNCVkeHUh?=
U251	M2LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwMUC1NlUh\|ryP	MVnTRW5ITVJ?
MMAC-SF	NUDBOpIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rTcmlEPTB;MD6xNFU{OSEQvF2=	MYDTRW5ITVJ?
BB65-RCC	NViwXmI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUT4Z5dvUUN3ME2wMlExPTV2IN88US=>	MlrWV2FPT0WU
NKM-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnQS5M1UUN3ME2wMlExPjZ4IN88US=>	NGPMfpVUSU6JRWK=
HD-MY-Z	Mm\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTxdVlKSzVyPUCuNVA5PzNizszN	M4PUNnNCVkeHUh?=
TGBC11TKB	NGfWemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwMUC5NFMh\|ryP	NEjlbIRUSU6JRWK=
COLO-679	NVzVbGtKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYe1PFJ5UUN3ME2wMlEyOjFzIN88US=>	MWXTRW5ITVJ?
TE-8	NVOyS2RkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTBwMUGyOlQh\|ryP	Mki2V2FPT0WU
SK-MEL-28	NVnvUGdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\VcGhKSzVyPUCuNVE{OjFizszN	NILQSJpUSU6JRWK=
SH-4	M4Oye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3hNGJKSzVyPUCuNVE{PTZizszN	MmqyV2FPT0WU
KALS-1	M4n3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGO2OIVKSzVyPUCuNVE{QTNizszN	MX\TRW5ITVJ?
RKO	Mn\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLSTWM2OD1yLkGxO\|Y1KM7:TR?=	NGTyfI1USU6JRWK=
OMC-1	MljFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTBwMUG3PVch\|ryP	NI\BRWhUSU6JRWK=
BT-549	NF7GTWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jKfmlEPTB;MD6xNVc6QSEQvF2=	MX;TRW5ITVJ?
NCI-H28	NETqNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M36zXWlEPTB;MD6xNVgyPyEQvF2=	MofQV2FPT0WU
RXF393	NGCwe\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETuVHpKSzVyPUCuNVE6QDJizszN	NHPzZ29USU6JRWK=
COLO-829	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnzb2RmUUN3ME2wMlEzODB3IN88US=>	MXHTRW5ITVJ?
HMV-II	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[xZ5RKSzVyPUCuNVIxOiEQvF2=	NGi2NYVUSU6JRWK=
SW1990	NUTRR29bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HMTmlEPTB;MD6xNlE2PyEQvF2=	NHjRc5VUSU6JRWK=
NCI-H1437	NYPtSY5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\aTpluUUN3ME2wMlEzOTV5IN88US=>	MoqxV2FPT0WU
SNB75	M37tPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTUTWM2OD1yLkGyNVY6KM7:TR?=	MmOyV2FPT0WU
EW-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13vRWlEPTB;MD6xNlY3OSEQvF2=	MWfTRW5ITVJ?
SAS	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTBwMUK2PUDPxE1?	NYPyb4tzW0GQR1XS
NCI-H1666	M2qyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELnO4VKSzVyPUCuNVI4PzRizszN	M4nyXnNCVkeHUh?=
A375	MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXHTWM2OD1yLkGyO\|c5KM7:TR?=	MlvOV2FPT0WU
CAMA-1	M1LJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn2wTWM2OD1yLkGyPVI1KM7:TR?=	NUDOU5R2W0GQR1XS
HuP-T4	M2\WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnBUYVKSzVyPUCuNVI6PDNizszN	MV7TRW5ITVJ?
NCI-H292	MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHOPHJKSzVyPUCuNVMyOSEQvF2=	NH;UUFhUSU6JRWK=
PC-14	NFeyNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHFdXdtUUN3ME2wMlE{OjFzIN88US=>	MWjTRW5ITVJ?
BPH-1	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXC[JdlUUN3ME2wMlE{PDFizszN	M2LCbXNCVkeHUh?=
GAK	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjsToNKSzVyPUCuNVM2PjdizszN	NFHjNmtUSU6JRWK=
VMRC-RCZ	Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\6dmlEPTB;MD6xN\|c3OiEQvF2=	M3S3WXNCVkeHUh?=
SK-MEL-24	NYX3PWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwMUO4O{DPxE1?	NF3vdGVUSU6JRWK=
LB831-BLC	NVzEOZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3VNYZKSzVyPUCuNVM5QDNizszN	NIjBN4NUSU6JRWK=
NCI-H2452	MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMUO5OVYh\|ryP	NYjteXE5W0GQR1XS
RT-112	NX64[WU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPqRY5rUUN3ME2wMlE1ODN3IN88US=>	M4DzcXNCVkeHUh?=
GP5d	NIXCfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnEeFZKSzVyPUCuNVQyODRizszN	NH;kXlJUSU6JRWK=
LC-2-ad	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPyeWJTUUN3ME2wMlE1OTJzIN88US=>	M3PDc3NCVkeHUh?=
MPP-89	NI\CUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnSzTWM2OD1yLkG0NVI2KM7:TR?=	NID4N3BUSU6JRWK=
NUGC-3	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDTTWM2OD1yLkG0OFc5KM7:TR?=	MVPTRW5ITVJ?
GI-1	NYjaeJVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS0TWM2OD1yLkG0OVU5KM7:TR?=	NEjTTYFUSU6JRWK=
HCC1419	MorWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj4e\|k5UUN3ME2wMlE1PTd4IN88US=>	Mlf2V2FPT0WU
SW1573	NIW2WINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme0TWM2OD1yLkG0O\|U5KM7:TR?=	M3;ub3NCVkeHUh?=
NCI-H2347	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfKTWM2OD1yLkG0PFM6KM7:TR?=	NXj1bWZxW0GQR1XS
Mewo	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVviUHA2UUN3ME2wMlE1QDh7IN88US=>	M2PxXHNCVkeHUh?=
639-V	M{TyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTBwMUWwNVMh\|ryP	NUC4[XloW0GQR1XS
AsPC-1	NYHBWYM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HsXmlEPTB;MD6xOVIzPSEQvF2=	NWrSR4N2W0GQR1XS
NCI-H1648	MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFuwPYdKSzVyPUCuNVUzOzJizszN	NG\oe3VUSU6JRWK=
786-0	NG\qS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMUWzPFEh\|ryP	NXyyXmlzW0GQR1XS
ETK-1	NIPKc5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELXTJpKSzVyPUCuNVU6KM7:TR?=	MUnTRW5ITVJ?
BxPC-3	NUHpWW9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NViyWJZZUUN3ME2wMlE2QTZ4IN88US=>	MkS5V2FPT0WU
CAL-62	MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon0TWM2OD1yLkG2NVY6KM7:TR?=	NUPKelhmW0GQR1XS
HCC1937	NV36[XJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfIWZpKSzVyPUCuNVYzPzVizszN	NVzLSHhlW0GQR1XS
NCI-H1299	NUjkToRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XP[mlEPTB;MD6xOlI5PSEQvF2=	Ml3OV2FPT0WU
SW1088	NY[5doRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGO0NlhKSzVyPUCuNVY1OTNizszN	NXHP[pFmW0GQR1XS
FTC-133	NYC0c5F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMU[1OEDPxE1?	NWDMRVRzW0GQR1XS
OC-314	M1rCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3NTWM2OD1yLkG2Olkh\|ryP	NXTNPJE4W0GQR1XS
SCC-9	M{jYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTzdpRnUUN3ME2wMlE3PzF4IN88US=>	M3rydHNCVkeHUh?=
HT-1376	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3BWotKSzVyPUCuNVY6OzZizszN	MYDTRW5ITVJ?
U-2-OS	NGP0b4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvQTWM2OD1yLkG3NVc{KM7:TR?=	M2f0ZXNCVkeHUh?=
COLO-824	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jGOWlEPTB;MD6xO\|I6PCEQvF2=	M2PWfnNCVkeHUh?=
BB30-HNC	NIH4XoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jpcmlEPTB;MD6xO\|M{KM7:TR?=	NITCcYZUSU6JRWK=
NCI-H2087	MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLqTWM2OD1yLkG3N\|Y5KM7:TR?=	MXvTRW5ITVJ?
NCI-H2170	MlfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTBwMUe1N\|Yh\|ryP	MXfTRW5ITVJ?
SK-OV-3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrLcYxKSzVyPUCuNVc2PzFizszN	NX\XV\|VxW0GQR1XS
MZ7-mel	M3HaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjZR3VKSzVyPUCuNVc3PDlizszN	M4[0OnNCVkeHUh?=
NCI-H650	MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfPTmY4UUN3ME2wMlE4Pjh{IN88US=>	NYrENmJDW0GQR1XS
KOSC-2	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4LDb2lEPTB;MD6xO\|c{PCEQvF2=	NYnuWlF4W0GQR1XS
SCC-4	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET1dYRKSzVyPUCuNVc4PzdizszN	M3npdnNCVkeHUh?=
MDA-MB-157	NULwWIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fzVGlEPTB;MD6xPFA5OiEQvF2=	NUTydGEzW0GQR1XS
KYSE-520	NGDMUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjWb2h5UUN3ME2wMlE5OiEQvF2=	NUDPUJc1W0GQR1XS
LK-2	NV3PeGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\PeWlEPTB;MD6xPFMxOyEQvF2=	MmH5V2FPT0WU
KNS-81-FD	Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjWOIJKSzVyPUCuNVg{QTRizszN	NWW0TG5SW0GQR1XS
IGROV-1	NUP1bFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjKTWM2OD1yLkG4OFQ{KM7:TR?=	M1i0enNCVkeHUh?=
DEL	NYS0cJI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfKTJdKSzVyPUCuNVg1PSEQvF2=	NHfXeVBUSU6JRWK=
NCI-H1395	NGDtSWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3HTWM2OD1yLkG4OlgzKM7:TR?=	NGr5cJVUSU6JRWK=
JEG-3	NXGwOIxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjnTWM2OD1yLkG4O\|A2KM7:TR?=	NXiwVFhtW0GQR1XS
BCPAP	NVTKcI9PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TLNmlEPTB;MD6xPFg4OiEQvF2=	NEDFdYhUSU6JRWK=
CAL-27	NWX6eYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17udGlEPTB;MD6xPVAzOiEQvF2=	MlfXV2FPT0WU
RD	MoO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTBwMUmxNVMh\|ryP	NIiwWoFUSU6JRWK=
RVH-421	MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M17wN2lEPTB;MD6xPVEyPiEQvF2=	NUX2dGpPW0GQR1XS
Capan-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwMUmyOVYh\|ryP	NW\od5FWW0GQR1XS
COLO-680N	M3v2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwMUmzOlQh\|ryP	MYHTRW5ITVJ?
NCI-H1650	Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jZXWlEPTB;MD6yNFA2PyEQvF2=	MVnTRW5ITVJ?
SBC-5	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;CTWM2OD1yLkKwNVE5KM7:TR?=	NY\5d\|JvW0GQR1XS
U031	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVP1[YVqUUN3ME2wMlIxPTR5IN88US=>	NWHGWo1pW0GQR1XS
S-117	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGD6XIxKSzVyPUCuNlA2PjRizszN	NGHmPGlUSU6JRWK=
DoTc2-4510	MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMkC3Olkh\|ryP	NUTyPZdnW0GQR1XS
AM-38	MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DNSWlEPTB;MD6yNFg1QCEQvF2=	MXvTRW5ITVJ?
A172	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvWVYhKSzVyPUCuNlExOjJizszN	MmrtV2FPT0WU
HPAF-II	NWPsSZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLKfWhKSzVyPUCuNlEzPjRizszN	NVfzb5VEW0GQR1XS
769-P	M3PwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vkSmlEPTB;MD6yNVI5KM7:TR?=	MnLuV2FPT0WU
MFE-280	M2\rS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rMemlEPTB;MD6yNVI6QCEQvF2=	MXjTRW5ITVJ?
TE-9	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwMkG3PFYh\|ryP	MkW0V2FPT0WU
C2BBe1	NFfWeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLUTWM2OD1yLkKyNVkh\|ryP	MkXzV2FPT0WU
EoL-1-cell	NEG3RmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTBwMkKyNFMh\|ryP	M3fUTHNCVkeHUh?=
G-361	NWPqUIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLJTWM2OD1yLkKyOlgzKM7:TR?=	NI[zUWhUSU6JRWK=
KYSE-270	M3LzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMkOwPFQh\|ryP	NILsSIVUSU6JRWK=
TK10	NV2xSJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3npOmlEPTB;MD6yN\|EyPyEQvF2=	MUjTRW5ITVJ?
ML-2	NEXEeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4Dm[GlEPTB;MD6yN\|EyQSEQvF2=	MV7TRW5ITVJ?
MHH-ES-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTBwMkO2PFEh\|ryP	Mn3EV2FPT0WU
BHY	NFnVZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGS0XnBKSzVyPUCuNlM3QTFizszN	NGjuenpUSU6JRWK=
LS-513	MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwMkO5OlEh\|ryP	M4PkVXNCVkeHUh?=
COLO-678	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33KeWlEPTB;MD6yOFA1PCEQvF2=	MWjTRW5ITVJ?
NCI-H747	MlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\ieWVPUUN3ME2wMlI1OTZ7IN88US=>	NFfHeIZUSU6JRWK=
K5	NGmydpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoixTWM2OD1yLkK0N\|gh\|ryP	NYe2fndmW0GQR1XS
OS-RC-2	NVjKOZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PZeGlEPTB;MD6yOFUxQSEQvF2=	MlziV2FPT0WU
KINGS-1	Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\5XHBZUUN3ME2wMlI1PTJ7IN88US=>	Mo\zV2FPT0WU
SCC-25	Ml7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fRRWlEPTB;MD6yOFU3OyEQvF2=	NIjBcpJUSU6JRWK=
CAPAN-1	NGfUSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTBwMkS3PFMh\|ryP	M1LTVHNCVkeHUh?=
ESS-1	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjIUFNDUUN3ME2wMlI1QDB3IN88US=>	NHfWOVBUSU6JRWK=
TE-6	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TrVmlEPTB;MD6yOVc2KM7:TR?=	MnnwV2FPT0WU
LB2518-MEL	NH3ISlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMkW3O\|ch\|ryP	NGXNUGlUSU6JRWK=
COLO-800	MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjXOGRiUUN3ME2wMlI2QDF{IN88US=>	M3vwSHNCVkeHUh?=
LU-134-A	M2nQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMk[xN\|Yh\|ryP	MmHyV2FPT0WU
NCI-H1155	M1zuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfl[3BKSzVyPUCuNlYyPjJizszN	NVLPd3FVW0GQR1XS
MFM-223	MlvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{f1d2lEPTB;MD6yOlM3OyEQvF2=	M4PRdHNCVkeHUh?=
HTC-C3	NGDYZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIfxTWNKSzVyPUCuNlY2ODZizszN	NVzYNVJTW0GQR1XS
HCT-116	NU\xToJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvE[WJKSzVyPUCuNlY2QTlizszN	MYLTRW5ITVJ?
Ca-Ski	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrnR2dKSzVyPUCuNlY3PzhizszN	MmnBV2FPT0WU
SBC-1	NXz3S2s4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS5[ndPUUN3ME2wMlI3PzR{IN88US=>	NYrTcJAyW0GQR1XS
NB69	NIrBfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHGwR3pKSzVyPUCuNlcxQDdizszN	Mn7jV2FPT0WU
J82	NUG2NWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorBTWM2OD1yLkK3NlY2KM7:TR?=	NIDyZoVUSU6JRWK=
U-118-MG	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnP5TWM2OD1yLkK3OVc6KM7:TR?=	MmW5V2FPT0WU
NCI-H1355	NHjPVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrmTWM2OD1yLkK4NFc1KM7:TR?=	NGGwXllUSU6JRWK=
NCI-H1048	Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjRTWM2OD1yLkK4PVU3KM7:TR?=	M4\EV3NCVkeHUh?=
SW954	M4DZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMkmyNlch\|ryP	NFrwfpZUSU6JRWK=
NMC-G1	NIjhbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUP4SWExUUN3ME2wMlI6Ojd5IN88US=>	MlT2V2FPT0WU
SW1710	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\NTnJlUUN3ME2wMlI6PDl2IN88US=>	MV3TRW5ITVJ?
KY821	NWHlVIFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3iTWM2OD1yLkK5PFczKM7:TR?=	MYPTRW5ITVJ?
HCC38	NWDxc244T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HwXGlEPTB;MD6zNFA4QCEQvF2=	NVj2WYYzW0GQR1XS
NCI-SNU-5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzZZnRMUUN3ME2wMlMxPTRizszN	NHLzXGVUSU6JRWK=
ES8	M{HGfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTBwM{C3PFQh\|ryP	NH3ZcFBUSU6JRWK=
COLO-792	NEO1[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwM{GyOVEh\|ryP	MUnTRW5ITVJ?
BFTC-905	NUHERnJrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHf6d5hKSzVyPUCuN\|E2OjFizszN	M1jXNnNCVkeHUh?=
ChaGo-K-1	NIDMd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3H0RWlEPTB;MD6zNVcyPSEQvF2=	NVfQUGpKW0GQR1XS
Daoy	NX;DfIRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwM{G3NlMh\|ryP	M2ToRXNCVkeHUh?=
SJSA-1	NXS4THo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{m3S2lEPTB;MD6zNVg1PyEQvF2=	NHnuU3ZUSU6JRWK=
KNS-62	NEDSPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmntTWM2OD1yLkOyNFg5KM7:TR?=	MVTTRW5ITVJ?
CAKI-1	NVLYTGFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwM{KxNVEh\|ryP	M4PlNXNCVkeHUh?=
UACC-62	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwM{KyNlch\|ryP	NHjL[YNUSU6JRWK=
HuCCT1	M2PufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfRNpZtUUN3ME2wMlMzOjh\|IN88US=>	MVHTRW5ITVJ?
CTB-1	MnHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX2TWM2OD1yLkOyO\|U{KM7:TR?=	MYTTRW5ITVJ?
NTERA-S-cl-D1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TXSGlEPTB;MD6zNlg{PiEQvF2=	NXHmPYZ7W0GQR1XS
T-24	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvBRYpKSzVyPUCuN\|MyPTlizszN	NHzWe2hUSU6JRWK=
KYSE-70	NXrZXWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TtcGlEPTB;MD6zN\|I5OyEQvF2=	Moq4V2FPT0WU
SW626	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XFOGlEPTB;MD6zN\|U{OiEQvF2=	NIfkTJpUSU6JRWK=
LB996-RCC	MkPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwM{O2NVkh\|ryP	M4foXHNCVkeHUh?=
DMS-273	MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;CeWlEPTB;MD6zN\|kyPiEQvF2=	M17rdnNCVkeHUh?=
SW1783	NVjFVohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwM{O5PVch\|ryP	MVvTRW5ITVJ?
KU812	Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3MVJROUUN3ME2wMlM1ODN6IN88US=>	M4DoeHNCVkeHUh?=
HSC-2	NH3jVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIL2TohKSzVyPUCuN\|QxPTNizszN	M4X2SXNCVkeHUh?=
A3-KAW	M4Lw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzIb5JIUUN3ME2wMlM1OTZ{IN88US=>	M3T1PXNCVkeHUh?=
COLO-684	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT0TWM2OD1yLkO0OVAyKM7:TR?=	M3rxZnNCVkeHUh?=
NCI-H2405	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLvZpRKSzVyPUCuN\|Q3OzFizszN	NFLnT25USU6JRWK=
NCI-H2228	MmPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrwZ2EyUUN3ME2wMlM2OzV5IN88US=>	NX\nZo13W0GQR1XS
NB13	NIC3SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGW1UZdKSzVyPUCuN\|Y5OjlizszN	M4TxXnNCVkeHUh?=
no-11	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLmSlVkUUN3ME2wMlM3QTVizszN	MXzTRW5ITVJ?
DK-MG	NIXq[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLFTWM2OD1yLkO3NVg5KM7:TR?=	NUTnUWNTW0GQR1XS
NBsusSR	NV\3[Jl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwM{eyPFUh\|ryP	MkTVV2FPT0WU
KP-N-YS	M{\qV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHyeY96UUN3ME2wMlM4PDZ\|IN88US=>	NUDYd5BVW0GQR1XS
CFPAC-1	M{L3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\6VGlEPTB;MD6zO\|UyQCEQvF2=	MX;TRW5ITVJ?
KARPAS-45	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrNVVVKSzVyPUCuN\|c5PjJizszN	NXTsRoFiW0GQR1XS
NCI-H1793	NEjBU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPGOpJGUUN3ME2wMlM5PTFizszN	MnHxV2FPT0WU
HCE-T	MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moi2TWM2OD1yLkO4OlA{KM7:TR?=	NETaPHBUSU6JRWK=
NCI-H520	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{S1cGlEPTB;MD6zPFcxOyEQvF2=	MlzPV2FPT0WU
HCC2157	M3G5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwM{i3PFEh\|ryP	MVLTRW5ITVJ?
EW-18	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfQTWM2OD1yLkO4PVQyKM7:TR?=	MoDSV2FPT0WU
RO82-W-1	NXf0R4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHyTWM2OD1yLkO5Olk6KM7:TR?=	NG\IdHNUSU6JRWK=
HuP-T3	NF3lbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPEW41KSzVyPUCuOFAyPDNizszN	M{nuOHNCVkeHUh?=
PANC-10-05	NFznTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnH4TWM2OD1yLkSxNVch\|ryP	M330SnNCVkeHUh?=
NCI-H1703	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTMTWM2OD1yLkSxOFQ3KM7:TR?=	MojCV2FPT0WU
TE-10	M1jQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLFTWM2OD1yLkSxOFQ4KM7:TR?=	NX7tb2lxW0GQR1XS
HOS	NHHyV2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITSWlZKSzVyPUCuOFE3QDJizszN	M{X5SHNCVkeHUh?=
LN-405	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwNEG2PFch\|ryP	MXHTRW5ITVJ?
A427	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPkVml2UUN3ME2wMlQyQThzIN88US=>	NI\jOZBUSU6JRWK=
CAL-12T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL1dY5TUUN3ME2wMlQzPzhizszN	M2PJfnNCVkeHUh?=
SW756	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2WyXGlEPTB;MD60OFE5OyEQvF2=	NXTab5ZjW0GQR1XS
YAPC	NIiwfGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnrUYZPUUN3ME2wMlQ2ODhizszN	NH\MOXVUSU6JRWK=
GOTO	NIOxVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4W1TmlEPTB;MD60OVE3KM7:TR?=	MYfTRW5ITVJ?
C3A	NFLKXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfU[3AxUUN3ME2wMlQ2PDN5IN88US=>	M{LBZXNCVkeHUh?=
UM-UC-3	M3nBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNEW0O{DPxE1?	NXfqd4JQW0GQR1XS
NCI-H1573	M{naV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF64U5BKSzVyPUCuOFU2PjlizszN	NH;0PJNUSU6JRWK=
LS-411N	NVr5d2g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLjO2dKSzVyPUCuOFY2OjdizszN	Mom3V2FPT0WU
COR-L23	NX3YR4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm4VJNKSzVyPUCuOFY4PjRizszN	MVPTRW5ITVJ?
HCE-4	Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwNEe0OFYh\|ryP	NFr6UGNUSU6JRWK=
NCI-H2291	NGjB[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r5e2lEPTB;MD60O\|g6PiEQvF2=	NETZeZVUSU6JRWK=
A101D	M3nqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK2TWM2OD1yLkS4NFU{KM7:TR?=	NWT3bFR4W0GQR1XS
HT-3	NWX2N2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLTUlhWUUN3ME2wMlQ5OjF5IN88US=>	MkHDV2FPT0WU
HOP-62	NIn4ZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjwV\|V2UUN3ME2wMlQ6QDZ3IN88US=>	MVvTRW5ITVJ?
PC-3	NIHobolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2n5[WlEPTB;MD61NVUxPyEQvF2=	MXrTRW5ITVJ?
CTV-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIm3bG1KSzVyPUCuOVI3PjlizszN	NYWwXGdWW0GQR1XS
PANC-08-13	NHP6emJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjLdmtKSzVyPUCuOVMyPzdizszN	NHf1cYtUSU6JRWK=
CAL-120	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNUOzPVkh\|ryP	MVPTRW5ITVJ?
UMC-11	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwNUWyN\|Qh\|ryP	M4fsNHNCVkeHUh?=
MSTO-211H	NXPoO4lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TxWmlEPTB;MD61OVc3OiEQvF2=	NYLUVVl2W0GQR1XS
NCI-H2126	M2DaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFm3PHRKSzVyPUCuOVY5OTVizszN	MWXTRW5ITVJ?
SNU-C2B	M1WxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnWTWM2OD1yLkW3PVc4KM7:TR?=	M1mzenNCVkeHUh?=
DBTRG-05MG	M{jmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnn4TWM2OD1yLkW4NFU{KM7:TR?=	M1rTW3NCVkeHUh?=
MKN1	NWG3VoJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXCSYM4UUN3ME2wMlU5Pzh\|IN88US=>	MVTTRW5ITVJ?
ES3	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlq3TWM2OD1yLkW5NVI1KM7:TR?=	NX7uR\|VnW0GQR1XS
OVCAR-3	MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rxRWlEPTB;MD61PVM1OSEQvF2=	MX\TRW5ITVJ?
ACHN	NVj2XlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHS2VlRKSzVyPUCuOlA2PjlizszN	Mn;wV2FPT0WU
SW872	M1P5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r6V2lEPTB;MD62NFc3OyEQvF2=	MXvTRW5ITVJ?
CP66-MEL	NXT1VlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwNkC5Olkh\|ryP	MnLWV2FPT0WU
NCI-H661	M4TzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XYUGlEPTB;MD62NVExPCEQvF2=	M4P4OnNCVkeHUh?=
UACC-893	NGTZeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rGR2lEPTB;MD62N\|Y5OSEQvF2=	M1L5cXNCVkeHUh?=
JVM-3	NV3IelVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTBwNkO4NFQh\|ryP	MV3TRW5ITVJ?
SF268	NFO5eXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwNkSzOFkh\|ryP	M3naT3NCVkeHUh?=
OCI-AML2	M2\QW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jjc2lEPTB;MD62OVM6PyEQvF2=	M2TEb3NCVkeHUh?=
RPMI-8226	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIrVd3RKSzVyPUCuOlY{OjNizszN	MUHTRW5ITVJ?
MKN28	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XnOmlEPTB;MD62OlYzPCEQvF2=	NXzN[YdvW0GQR1XS
MDA-MB-453	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M173bmlEPTB;MD62O\|E5KM7:TR?=	M2jwUHNCVkeHUh?=
BV-173	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPrTWM2OD1yLk[4Olc6KM7:TR?=	MoTHV2FPT0WU
NCI-H358	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTBwNki3NlYh\|ryP	M2rvfHNCVkeHUh?=
NCI-H1651	Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jpb2lEPTB;MD63JO69VQ>?	NVjSVINIW0GQR1XS
MDA-MB-415	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLWTWM2OD1yLkewPFI6KM7:TR?=	M1iwXnNCVkeHUh?=
8305C	NXj4NmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTBwN{K0PVgh\|ryP	MYPTRW5ITVJ?
EFM-19	M3X1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXLFNotyUUN3ME2wMlc{PjdzIN88US=>	NWm2VG9UW0GQR1XS
RERF-LC-MS	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHyRXBKUUN3ME2wMlc1PjF\|IN88US=>	MlPVV2FPT0WU
A388	NXLRWIp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwN{[0Olch\|ryP	NY\QdXhJW0GQR1XS
GI-ME-N	NIn5e5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoP3TWM2OD1yLke3NlM2KM7:TR?=	Mm\6V2FPT0WU
IGR-1	NF:4[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHsfGxKSzVyPUCuO\|kxPDNizszN	M3vqXHNCVkeHUh?=
LNCaP-Clone-FGC	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PkRmlEPTB;MD64NFAxPCEQvF2=	NGTldGtUSU6JRWK=
SK-MEL-3	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{W1dWlEPTB;MD64NVUxQCEQvF2=	NUn5c3d4W0GQR1XS
UACC-257	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTKUYhKSzVyPUCuPFIzOzFizszN	M1HaOnNCVkeHUh?=
OE33	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTBwOEWxNFEh\|ryP	MknLV2FPT0WU
QIMR-WIL	NFzVfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwOEWxOFEh\|ryP	NWLrNIdVW0GQR1XS
NCI-H2009	NETSe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHPTWM2OD1yLki1N\|EyKM7:TR?=	MlvsV2FPT0WU
NCI-H522	NIrXOYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEm2V\|hKSzVyPUCuPFc4QDNizszN	NH3wUVJUSU6JRWK=
Saos-2	M3G2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{X3TWlEPTB;MD64O\|g4OSEQvF2=	MUjTRW5ITVJ?
NB17	Mmf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnm3TWM2OD1yLki4NFI2KM7:TR?=	NUXuTZQ5W0GQR1XS
D-392MG	NETM[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTBwOEmzOVYh\|ryP	MnTMV2FPT0WU
SHP-77	M335eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwOUC0PFUh\|ryP	MlvDV2FPT0WU
SK-MEL-30	NIHwPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7sTWM2OD1yLkmxNVg2KM7:TR?=	M4DKZnNCVkeHUh?=
GCIY	M1nuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTSTWM2OD1yLkmxPFQ{KM7:TR?=	NUDUZ2FmW0GQR1XS
HCC70	NYPtSHJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwOUKwOVkh\|ryP	M{[wTHNCVkeHUh?=
LU-65	MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTBwOUK1PVEh\|ryP	MWfTRW5ITVJ?
NCI-H1563	Ml\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLTTWM2OD1yLkm0PFY2KM7:TR?=	MlfQV2FPT0WU
KURAMOCHI	NGjpNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3VZ\|BKSzVyPUCuPVUyQTJizszN	M2XkR3NCVkeHUh?=
PA-1	NYfsW5U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXu1cnU5UUN3ME2wMlk2PDJ2IN88US=>	MXTTRW5ITVJ?
NOS-1	M1nGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTKTWM2OD1yLkm3OFg6KM7:TR?=	MX3TRW5ITVJ?
NCI-H69	Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PtVmlEPTB;MD65O\|Y{PCEQvF2=	MkfwV2FPT0WU
KYSE-450	NELL[5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn5TWM2OD1yLkm4OlI3KM7:TR?=	Ml7IV2FPT0WU
8505C	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXRTWM2OD1yLkm5PVgzKM7:TR?=	MnLvV2FPT0WU
TGBC24TKB	NIrXR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTFwMECwPFQh\|ryP	NIDWS5hUSU6JRWK=
PFSK-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TMV2lEPTB;MT6wNVQzQCEQvF2=	NWLTOpFkW0GQR1XS
EKVX	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\pSGd3UUN3ME2xMlA{OTJzIN88US=>	NH;tdIdUSU6JRWK=
RCM-1	MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorHTWM2OD1zLkC1OVA4KM7:TR?=	MV;TRW5ITVJ?
SW900	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\iOWlEPTB;MT6wO\|g{KM7:TR?=	NFX6fY1USU6JRWK=
D-542MG	M{XJOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX6VplKSzVyPUGuNFc5PTVizszN	M3KxNHNCVkeHUh?=
SK-PN-DW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mln1TWM2OD1zLkGwNFU3KM7:TR?=	NHTBSnhUSU6JRWK=
NCI-H727	NVvlWHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPKR2xFUUN3ME2xMlExOTV2IN88US=>	NVXhNm5rW0GQR1XS
SW837	NXHq[FQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XUXGlEPTB;MT6xNFk2PCEQvF2=	MWHTRW5ITVJ?
BT-20	Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3ZbINzUUN3ME2xMlEyOjB2IN88US=>	MXrTRW5ITVJ?
RH-18	MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rVTmlEPTB;MT6xN\|ExOyEQvF2=	MoSzV2FPT0WU
TE-12	NXf6VphDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DrT2lEPTB;MT6xN\|M{OyEQvF2=	NYTnRYQxW0GQR1XS
NB10	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPBTWM2OD1zLkGzN\|Q1KM7:TR?=	MWrTRW5ITVJ?
AU565	NIHJNmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHpR2FKSzVyPUGuNVU6PzNizszN	NYLIUo96W0GQR1XS
OAW-42	M{j4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTFwMUizNFYh\|ryP	NX;DZZlCW0GQR1XS
DJM-1	M4XlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnrfYlrUUN3ME2xMlE6QDhzIN88US=>	M1fMUHNCVkeHUh?=
HH	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\SdWlEPTB;MT6yN\|g{OSEQvF2=	MkDiV2FPT0WU
LAMA-84	NEe3RZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzDZ2hKSzVyPUGuNlc{QTRizszN	MmnoV2FPT0WU
KNS-42	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\qWnZMUUN3ME2xMlMxOjl4IN88US=>	NIfMPVBUSU6JRWK=
NCI-H2052	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHJZ4tKSzVyPUGuN\|A2ODdizszN	NVXqW3V2W0GQR1XS
MLMA	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFwM{K0NFch\|ryP	MmD4V2FPT0WU
NB12	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPSdmVKSzVyPUGuN\|U3OzZizszN	M4PuVnNCVkeHUh?=
NCI-H1838	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTFwM{[zNFYh\|ryP	M{XDUHNCVkeHUh?=
NCI-H526	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTFwM{e4OVMh\|ryP	NHf3flJUSU6JRWK=
LS-123	NH:4[4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmKxTWM2OD1zLkO5NFk1KM7:TR?=	Mlz3V2FPT0WU
HDLM-2	M4D1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3r5R2lEPTB;MT6zPVI4OSEQvF2=	M4T5O3NCVkeHUh?=
MC-IXC	NWLHOYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MljnTWM2OD1zLkSyN\|cyKM7:TR?=	NGHmcWFUSU6JRWK=
HCT-15	MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvSTWM2OD1zLkSzNFY5KM7:TR?=	NHvleXRUSU6JRWK=
NCI-H596	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrUTWM2OD1zLkS1NFYyKM7:TR?=	MXPTRW5ITVJ?
ZR-75-30	NHW2RWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnZTWM2OD1zLkS3NFgzKM7:TR?=	M3LKNHNCVkeHUh?=
A704	MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInsVoxKSzVyPUGuOlY2PjNizszN	NETVVHJUSU6JRWK=
OVCAR-4	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LUUGlEPTB;MT62PVYxPyEQvF2=	MUTTRW5ITVJ?
SW1417	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGixZpBKSzVyPUGuO\|I5PDlizszN	M{D1cXNCVkeHUh?=
CAS-1	NF7UW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TKe2lEPTB;MT63N\|k{PiEQvF2=	MYfTRW5ITVJ?
IST-SL1	NYDVZnpbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X5OWlEPTB;MT63PVc2QSEQvF2=	NVTCXXdRW0GQR1XS
A253	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH1U4d[UUN3ME2xMlgzOjN7IN88US=>	MXLTRW5ITVJ?
EW-16	NWrWZopjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfYb5hKSzVyPUGuPFI5PzVizszN	M2fOb3NCVkeHUh?=
SK-NEP-1	NWLqNJFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLoR4tKSzVyPUGuPFY6QDhizszN	M4PMUHNCVkeHUh?=
NCI-H226	NILzbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrITWM2OD1zLki5N\|U6KM7:TR?=	MWjTRW5ITVJ?
HOP-92	NHrTfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vEVmlEPTB;MT65OlA6QSEQvF2=	NF\aXJBUSU6JRWK=
NCI-H441	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTJwMEKzN\|ch\|ryP	MlzrV2FPT0WU
LU-139	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrTflNKSzVyPUKuNFMyOTRizszN	NEPYWZBUSU6JRWK=
SJRH30	NEnrbmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ZVGlEPTB;Mj6wOFI2OyEQvF2=	MljzV2FPT0WU
MG-63	NIjjV5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fmXWlEPTB;Mj6xOFEyOSEQvF2=	NELhVVlUSU6JRWK=
NH-12	NIntcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonZTWM2OD1{LkG1NFA3KM7:TR?=	NIn3S2dUSU6JRWK=
NB7	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrJTWM2OD1{LkG5Olc{KM7:TR?=	NH3ub4tUSU6JRWK=
LB771-HNC	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJwMkC1PVUh\|ryP	MXHTRW5ITVJ?
HCC1569	M2eyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGK4dJFKSzVyPUKuNlQ2QDNizszN	NFn5ZW5USU6JRWK=
D-283MED	M4m2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17HemlEPTB;Mj6yOFc5OiEQvF2=	M3LueXNCVkeHUh?=
J-RT3-T3-5	NF7mNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3vTWM2OD1{LkK1N\|UyKM7:TR?=	NH3COWFUSU6JRWK=
ATN-1	NUfoV4ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP1dYRKSzVyPUKuN\|MxQDJizszN	MlH0V2FPT0WU
HCC1954	NY\FZ2pUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFntUGlKSzVyPUKuN\|Q1ODhizszN	M3PoSnNCVkeHUh?=
SCC-15	NUPUZVNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXwe3hKSzVyPUKuN\|k{OTJizszN	NIfhVpFUSU6JRWK=
COLO-668	M2PPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDIZ5JKSzVyPUKuOFMzKM7:TR?=	M1\iVXNCVkeHUh?=
LB373-MEL-D	NInwblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfkVJJKSzVyPUKuOVQ3PzdizszN	MlvzV2FPT0WU
no-10	M4nZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkK4TWM2OD1{LkW0PVQ4KM7:TR?=	NWXFN4NFW0GQR1XS
HT-1197	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;oZWlEPTB;Mj62N\|E5QCEQvF2=	M1TwNXNCVkeHUh?=
DU-145	MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7EU25KSzVyPUKuO\|kyPjJizszN	NYjrbHhKW0GQR1XS
SK-N-AS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nMfWlEPTB;Mj64OFY6OiEQvF2=	NVLvZWFlW0GQR1XS
MOLT-4	NWXKNZpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJwOEWzNlIh\|ryP	NVjrUlF{W0GQR1XS
EW-22	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHhOJVKSzVyPUKuPVI5PDFizszN	M3HLXnNCVkeHUh?=
DB	M36zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnOXlhYUUN3ME2yMlk4PzV7IN88US=>	NUXTcoNyW0GQR1XS
HL-60	M{XUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTrdYRKSzVyPUOuNFQ{PzZizszN	M3nmUXNCVkeHUh?=
SK-N-DZ	NEPLcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLpcGxyUUN3ME2zMlA2ODd3IN88US=>	NUTB[\|BFW0GQR1XS
NY	M1[1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljHTWM2OD1\|LkC4OVQzKM7:TR?=	NWO3RoxMW0GQR1XS
T47D	NF;UeHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjU[GZqUUN3ME2zMlExPTV6IN88US=>	M1:zRXNCVkeHUh?=
NCI-H2029	M3yydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTNwMkK0O\|ch\|ryP	NF7XeYFUSU6JRWK=
KARPAS-299	M135NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTNwMk[wNlch\|ryP	NUXpdnkzW0GQR1XS
KM-H2	NVz5[ms6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLvfXNKSzVyPUOuN\|A3QCEQvF2=	MlzWV2FPT0WU
CHP-134	NWDocVh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXwTWM2OD1\|LkS3N\|kh\|ryP	MWnTRW5ITVJ?
22RV1	NF\NOHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HyUWlEPTB;Mz60PVE3QCEQvF2=	MVLTRW5ITVJ?
NB5	M4PWemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrzTWM2OD1\|LkWwOlg6KM7:TR?=	MX3TRW5ITVJ?
CW-2	NHnXOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHf1T\|FKSzVyPUOuOVU{OTRizszN	MYHTRW5ITVJ?
EFO-21	NIXOUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoWyTWM2OD1\|LkW2PVQh\|ryP	NX\ifm9OW0GQR1XS
HuH-7	NEDvWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTKb\|RKSzVyPUOuOVg1OTRizszN	NHnVV4ZUSU6JRWK=
ALL-PO	MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PTSGlEPTB;Mz62NlM{PSEQvF2=	MYXTRW5ITVJ?
EM-2	NVvGOlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjpVHVrUUN3ME2zMlY6ODFzIN88US=>	MmTGV2FPT0WU
KLE	NGDGWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjld25PUUN3ME2zMlc{ODJ7IN88US=>	MYjTRW5ITVJ?
NEC8	NF7wN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTNwOUG4NFgh\|ryP	MWnTRW5ITVJ?
KP-N-YN	NYrLU5dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVn3UnloUUN3ME2zMlk{PDd4IN88US=>	M1HBWnNCVkeHUh?=
SK-MEL-1	Ml3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzlTWM2OD12LkCzOVE5KM7:TR?=	NYfsSlU2W0GQR1XS
CAL-54	M3\temdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrw[G5KSzVyPUSuNFU6OSEQvF2=	NFzy[IlUSU6JRWK=
MS-1	M2D2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTRwMU[xOVUh\|ryP	NFnRO5lUSU6JRWK=
NCI-H209	M1L2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTXWWpDUUN3ME20MlI6QTl7IN88US=>	M4q5NnNCVkeHUh?=
NOMO-1	NEG1dZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn2TWM2OD12LkOyNVMyKM7:TR?=	MnfQV2FPT0WU
RPMI-2650	NHfuZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXLTWM2OD12LkO2N\|I4KM7:TR?=	Mk\pV2FPT0WU
NCI-H810	M17xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTRwM{m3N\|Yh\|ryP	MnzrV2FPT0WU
Ca9-22	NUf1RlRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jHbWlEPTB;ND60OVY6OSEQvF2=	NIfO[lNUSU6JRWK=
ES4	NE\LUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTRwNEewPVUh\|ryP	NVvXbodRW0GQR1XS
ES6	M4W5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTRwNEm2OVch\|ryP	M3;tbnNCVkeHUh?=
DMS-114	M1[5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTRwNUS2PVEh\|ryP	NF\2W3dUSU6JRWK=
ONS-76	M2Tudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoH2TWM2OD12LkW3PVUh\|ryP	MnOyV2FPT0WU
K-562	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jQTWlEPTB;ND63N\|gyPCEQvF2=	M2PpdXNCVkeHUh?=
MHH-NB-11	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTRwN{W0OlEh\|ryP	MYPTRW5ITVJ?
Calu-3	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nIb2lEPTB;ND63PFU1QCEQvF2=	MXLTRW5ITVJ?
HT55	MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPiTWM2OD12Lki0OVQ2KM7:TR?=	NI\MfJBUSU6JRWK=
SK-N-FI	NYO1fWVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGX4S3JKSzVyPUSuPFUxODlizszN	NFz0UINUSU6JRWK=
ES1	NUXiZnRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vGVWlEPTB;ND64OlA2PyEQvF2=	NVroNY5jW0GQR1XS
SF126	NWDTbZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknSTWM2OD12LkmzNVg1KM7:TR?=	MkLhV2FPT0WU
ES5	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHXTWM2OD13LkGyOFI4KM7:TR?=	M1H2T3NCVkeHUh?=
LoVo	NV[1b3NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFvBUZhKSzVyPUWuNVU5PzFizszN	NUTpOWxiW0GQR1XS
SNU-387	M3fCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTVwM{KzN\|kh\|ryP	MoS5V2FPT0WU
C8166	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XXbmlEPTB;NT6zOlM{QSEQvF2=	NH7kU5ZUSU6JRWK=
LS-1034	NX6zU2dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXMTWM2OD13LkSyN\|A4KM7:TR?=	NXPFWYFPW0GQR1XS
GR-ST	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTVwNUKyNFEh\|ryP	MoLKV2FPT0WU
NCI-H1092	M{LZNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjGTWM2OD13LkeyPFQ{KM7:TR?=	MlXoV2FPT0WU
647-V	M4riNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrsTWM2OD13Lke0O\|A3KM7:TR?=	NFKyZlBUSU6JRWK=
EW-13	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;RTWM2OD13Lke2OlI4KM7:TR?=	NV3hUGpSW0GQR1XS
KGN	MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnNTItCUUN3ME22MlA6QTJzIN88US=>	NGPBS3dUSU6JRWK=
D-423MG	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPj[odKSzVyPU[uOFAzQDRizszN	NVXBVpVwW0GQR1XS
ECC10	NEPtcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PlfWlEPTB;Nz6xNFExOSEQvF2=	M13DNHNCVkeHUh?=
TE-5	NWTZ[JFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXPSWlKSzVyPUeuOFEzQThizszN	MVnTRW5ITVJ?
P12-ICHIKAWA	NGm2eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTdwNEW1NlMh\|ryP	MkfRV2FPT0WU
NCI-H82	M3LRR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;ZbnJTUUN3ME23MlQ2PzBzIN88US=>	MUfTRW5ITVJ?
NCI-H1993	Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTdwOEOwOlMh\|ryP	NFHTUFVUSU6JRWK=
RH-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFPPO\|dKSzVyPUeuPFUzPDRizszN	M2\aR3NCVkeHUh?=
SW948	NWXRNJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXrLeWFFUUN3ME23Mlk3ODR7IN88US=>	M3vBb3NCVkeHUh?=
CAL-33	NFTvV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnCemZlUUN3ME23Mlk6QTN6IN88US=>	NGDYNo5USU6JRWK=
U-266	NX23Z4FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrUfJBKSzVyPUiuNVU4PzdizszN	NXfQfXU5W0GQR1XS
CAL-72	NEW3T3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlLjTWM2OD16LkKwN\|Ih\|ryP	MV\TRW5ITVJ?
SNU-423	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXPTWM2OD17LkO2OlY3KM7:TR?=	MnjXV2FPT0WU
KG-1	MmDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[zXmlEPTB;OT61PFQ2PiEQvF2=	Mn7TV2FPT0WU
HCC1395	NHLRSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3j2eGlEPTB;OT65NlM2OiEQvF2=	MnqzV2FPT0WU
BE-13	M3WwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLM[lI3UUN3ME2xNE45QDl{IN88US=>	MnLSV2FPT0WU
MKN7	NUHw[HBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;qW\|lKSzVyPUGwMlk4PjVizszN	NFuwdXlUSU6JRWK=
697	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEH3cm1KSzVyPUGxMlE1PzJizszN	M4LEbXNCVkeHUh?=
LU-135	NFPRfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PYVmlEPTB;MUGuNlMxPyEQvF2=	NHrhe41USU6JRWK=
ES7	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn0cJZEUUN3ME2xNU4{OzF\|IN88US=>	MV7TRW5ITVJ?
SK-HEP-1	NYHXVmV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\CTWM2OD1zMT63OlQ3KM7:TR?=	NIq0XmxUSU6JRWK=
BEN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTFzLki1NUDPxE1?	M3rDNXNCVkeHUh?=
NCI-H1770	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2foU2lEPTB;MUKuNVI3KM7:TR?=	NWjDdZVLW0GQR1XS
SW13	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq5VG9{UUN3ME2xNk4yPTRzIN88US=>	MljKV2FPT0WU
MZ1-PC	M3LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjJXmtGUUN3ME2xNk42PDV{IN88US=>	NInNelhUSU6JRWK=
Mo-T	NXPZWJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTF{Lke0NlEh\|ryP	MXjTRW5ITVJ?
HLE	NEnLOolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nZWWlEPTB;MUKuPFIyPSEQvF2=	NYC3NnA3W0GQR1XS
RCC10RGB	NEH4ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PNVmlEPTB;MUOuOlcyKM7:TR?=	Moj5V2FPT0WU
COLO-320-HSR	M1TaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF\|LkezPFEh\|ryP	MlrDV2FPT0WU
BHT-101	MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWzTWM2OD1zMz64N\|Q2KM7:TR?=	Mn;NV2FPT0WU
OCUB-M	NGXHdJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVr2SXVxUUN3ME2xOE4yPjB{IN88US=>	NFrhRoxUSU6JRWK=
MEG-01	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHy2cXdKSzVyPUG0MlM4ODhizszN	MYPTRW5ITVJ?
RS4-11	M1noW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnGe3h{UUN3ME2xOE44PDJizszN	MmCxV2FPT0WU
MN-60	NXHsUHpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkT5TWM2OD1zND63PFk1KM7:TR?=	MmXMV2FPT0WU
NCI-H1304	NIXIeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M365UGlEPTB;MUWuNFQzPSEQvF2=	NXq0R4dnW0GQR1XS
Ramos-2G6-4C10	M1XaeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\pTWM2OD1zNT6wOVgyKM7:TR?=	NUTLZno2W0GQR1XS
NCI-H2342	NHjBSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTF3LkKwOFQh\|ryP	NGX3S29USU6JRWK=
LAN-6	NVrsd2dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnfvTWM2OD1zNT60OFE1KM7:TR?=	M33FZnNCVkeHUh?=
JVM-2	NXHQVotpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml21TWM2OD1zNT61O\|Q5KM7:TR?=	NWHzW5hzW0GQR1XS
P30-OHK	NU\FN5BrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mly2TWM2OD1zNj6wOlE1KM7:TR?=	MVfTRW5ITVJ?
C-33-A	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPpTWM2OD1zNj62NlE1KM7:TR?=	MlLyV2FPT0WU
RPMI-8866	MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTF4Lki0PVYh\|ryP	M{XjdXNCVkeHUh?=
NCI-H630	NX3KVllYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTF4Lki1N\|ch\|ryP	NVfBWXo5W0GQR1XS
KYSE-140	NIXodYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTF5LkKwNlgh\|ryP	MoPzV2FPT0WU
T84	NGPE[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmizTWM2OD1zOD64Olk2KM7:TR?=	M2rHTHNCVkeHUh?=
KU-19-19	MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnflTWM2OD1zOD65OlA5KM7:TR?=	MXrTRW5ITVJ?
BALL-1	M4rKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPyTWM2OD1zOT6zN\|k6KM7:TR?=	NFLsbZRUSU6JRWK=
Calu-6	NV;YTJRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELtZmdKSzVyPUG5MlQ6OiEQvF2=	NF3YXldUSU6JRWK=
EGI-1	NFfIdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTF7LkW5PEDPxE1?	NGfIRoVUSU6JRWK=
MFH-ino	M4nKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DLc2lEPTB;MUmuO\|Q2PCEQvF2=	MXXTRW5ITVJ?
GB-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJyLkO1N\|Uh\|ryP	NF;1OnNUSU6JRWK=
NCI-H1693	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJyLk[1NFUh\|ryP	MmWxV2FPT0WU
SW1116	NVT4cW01T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLDdGNxUUN3ME2yNE46OzZ{IN88US=>	MUXTRW5ITVJ?
H-EMC-SS	M{LRbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2foRWlEPTB;MkKuNFQ2KM7:TR?=	MVHTRW5ITVJ?
D-502MG	Mof0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3y5PWlEPTB;MkKuPFI3OSEQvF2=	M4XIVXNCVkeHUh?=
IA-LM	MoG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULMfFF6UUN3ME2yN{4zPDl\|IN88US=>	MXLTRW5ITVJ?
SW1463	M33oZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ\|Lke5JO69VQ>?	NFXWNINUSU6JRWK=
JAR	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17PdGlEPTB;MkSuN\|I6OyEQvF2=	MX;TRW5ITVJ?
HT	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XlWWlEPTB;MkSuOFc2OyEQvF2=	MUHTRW5ITVJ?
LCLC-103H	M{W5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoGwTWM2OD1{ND64OFQ6KM7:TR?=	MVLTRW5ITVJ?
SNU-449	NWrQdmYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PQTGlEPTB;MkSuPFc1OSEQvF2=	MnfsV2FPT0WU
KE-37	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;3[mlEPTB;MkWuNFkzQCEQvF2=	MVPTRW5ITVJ?
NCI-H1623	M{jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTJ5LkGzNFMh\|ryP	M1G3e3NCVkeHUh?=
MOLT-13	NIL5bndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTJ5LkO1NVYh\|ryP	NIXZRY9USU6JRWK=
COLO-741	NFrO[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTNzLkOzN\|Mh\|ryP	NETFWoZUSU6JRWK=
NB6	M1HZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3rNWRKSzVyPUOyMlI5PzZizszN	MUXTRW5ITVJ?
MOLT-16	NIHwb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnm0TWM2OD1\|Mz6wNFU2KM7:TR?=	M4D4O3NCVkeHUh?=
IST-MES1	Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2P3dGlEPTB;M{SuNFU1OSEQvF2=	NVHPPYZsW0GQR1XS
A4-Fuk	NUj1RYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTyeGNKSzVyPUO1MlA3PiEQvF2=	NFfKd\|JUSU6JRWK=
CAL-85-1	NGS2cW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlm3TWM2OD1\|NT6yPFE4KM7:TR?=	MWLTRW5ITVJ?
CCRF-CEM	NUPJWXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnGUppKSzVyPUO3MlE2OzZizszN	NGPwZZpUSU6JRWK=
HAL-01	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDifoRKSzVyPUO4MlQ5QDlizszN	NFvCTnJUSU6JRWK=
HEL	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mny2TWM2OD12Mz6zOFA6KM7:TR?=	M{HZfXNCVkeHUh?=
EW-1	NX3xZZR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzaTWM2OD12Mz60O\|Y5KM7:TR?=	MYjTRW5ITVJ?
MDA-MB-231	NIT2c3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITodoFKSzVyPUS1MlEyQTlizszN	NHm4V4pUSU6JRWK=
ABC-1	M{HMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjHcVBIUUN3ME20Ok45PTN6IN88US=>	NX;hSWdyW0GQR1XS
NCI-H446	MmrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPzU\|lKSzVyPUS4MlUxPThizszN	NFLJeWNUSU6JRWK=
MHH-PREB-1	NWnC[VRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjtTWM2OD12OT62NFA4KM7:TR?=	NVX3So81W0GQR1XS
DOHH-2	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzZTWM2OD12OT62OlU3KM7:TR?=	NGPqfVBUSU6JRWK=
GCT	M{HGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[4WGhKSzVyPUS5MlY6PzZizszN	M1e5bXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	- Collapse Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Water	Insoluble
	Ethanol	'5 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953
Smiles	CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCC=C)C)OC)OC(=O)N)C)C)O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (HSP90) Signaling Pathway Map

HSP (HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (HSP90) Products

PU-H71 ^New

PU-H71 (NSC 750424) is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER155008 (C07) is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90. VER155008 inhibits autophagy and causes reduced levels of HSP90 client proteins.
Luminespib (NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Luminespib (AUY-922, NVP-AUY922) effectively downregulates and destabilizes the IGF-1Rβ protein and results in growth inhibition, autophagy and apoptosis. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG, NSC 707545, BMS 826476, KOS 1022) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin (NSC 122750) is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin attenuates virus infection-induced ALI (acute lung injury)/ARDS (acute respiratory distress syndrome) by reducing the host's inflammatory responses.
HSP990 (NVP-HSP990)

HSP990 (NVP-HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM. NVP-HSP990 induces cell cycle arrest and apoptosis.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)